Pablo Villoslada

Biography

 Co-founder. MD and PhD; Director of Neuroimmunology at University Hospital Clínic of Barcelona. Medical doctor and PhD in neuroimmunology, Pablo discovered the Bionure drug after more than 15 years of research in neurology and in the field of Multiple Sclerosis. He has published more than 80 peer-reviewed articles and 8 patents related to new therapies and diagnostic methods for neurological diseases and retina. He is Director of Neuroimmunology at Hospital Clínic-IDIBAPS and Medical Director at Genentech-Roche. Werner Baumann was born in Krefeld, Germany, on October 6, 1962. After studying economics at RWTH Aachen University and the University of Cologne, he joined Bayer in 1988. His first duties were in the Corporate Finance Department in Leverkusen. In 1991 he transferred to Bayer Hispania Comercial in Barcelona, Spain, to take up a position as controller, becoming assistant to the managing director in 1995. One year later, he moved to Bayer Corporation in Tarrytown, New York, latterly heading up the global Business Planning & Administration organization of the Diagnostics Business Group. In July 2002, Baumann returned to Germany to become a member of the Executive Committee and Head of Central Administration & Organization at Bayer HealthCare. In October 2003, he was appointed a member of the Board of Management of the newly formed subgroup Bayer HealthCare AG, also serving as that company’s Labor Director. As a member of the Board of Management and Labor Director of Bayer Schering Pharma AG, Berlin, Germany, from 2006 through September 2009, he actively participated in this company’s integration into the former HealthCare subgroup.  Effective January 1, 2010, Baumann was Chief Financial Officer of Bayer AG. From October 1, 2014, until his appointment as Chairman of the Board of Management, he was Chief Strategy and Portfolio Officer and also responsible for the Europe, Middle East and Africa Region.

Research Interest

 His area of research interest includes Neuroimmunology, in neurology and in the field of Multiple Sclerosis, new therapies and diagnostic methods for neurological diseases and retina.